Pablo Guala, MD
Cardiovascular Disease · Hialeah, FLNPI 1407953482
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,879 of the $17,823 with a category attached, or 66.6%. It is spread thinly across 37 manufacturers, the largest accounting for just 22.9%. Reporting peaked in 2022 at $5,230 and has fallen 88.4% since, to $604 in 2025.
Across 294 payments — averaging $60.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$4K
- Cordis US CORP.$4K
- Biotronik Inc.$2K
- Abbott$1K
- Medtronic$955
- Bard Peripheral Vascular, Inc.$919
- plus $5K from 31 others
Across 2 payments — averaging $63,960 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Withings, Inc.$128K
What the payments were for
- Consulting fees$3,60020%
- Food & beverage$11,87967%
- Education$870%
- Gifts$2,19512%
- Entertainment$630%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 32 | $4,081 |
| Cordis US CORP. | 5 | $3,660 |
| Biotronik Inc. | 24 | $2,467 |
| Abbott | 13 | $1,197 |
| Medtronic(2 entities) | 12 | $955 |
| Bard Peripheral Vascular, Inc. | 29 | $919 |
| Cardiovascular Systems Inc. | 8 | $533 |
| Novartis | 27 | $464 |
| Esperion Therapeutics, Inc. | 6 | $359 |
| Johnson & Johnson | 19 | $340 |
| Boston Scientific | 7 | $279 |
| Asahi Intecc USA, Inc. | 3 | $275 |
| Amgen | 12 | $268 |
| Amarin Pharma, Inc. | 15 | $257 |
| Merck | 13 | $243 |
| Cook Medical LLC | 9 | $177 |
| BD | 7 | $173 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $172 |
| Pfizer | 7 | $146 |
| Sanofi-aventis U.S. LLC | 7 | $119 |
| E.r. Squibb & Sons, L.L.C. | 5 | $107 |
| Kowa Pharmaceuticals America, Inc. | 5 | $84 |
| Heartflow, Inc. | 3 | $84 |
| Boehringer Ingelheim | 4 | $81 |
| Regeneron Healthcare Solutions, Inc. | 3 | $70 |
| AstraZeneca | 4 | $64 |
| Tactile Systems Technology Inc | 3 | $49 |
| Vital Connect, Inc | 1 | $26 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Biocompatibles, Inc. | 1 | $21 |
| Cashflow Solutions, LLC | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Kerecis Limited | 1 | $17 |
| Angiodynamics, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT Devices Und$2,689
- CORDIS S.M.A.R.T. CONTROL VASCULAR STENT SYSTEM$900
- Acticor$867
- Solia$867
- Rivacor$867
- Edora$867
- BioMonitor$867
- Turbo Elite$534
- AVEIR$415
- JOT DX$373
- Acticor 7 VR-T DX$346
- VENOVO$345
- NEXLIZET$288
- NEXLETOL$288
- Resolute$235
- (P84) IGT Devices Systems$149
- WATCHMAN FLX$147
- GALLANT$143
- Edora 8 DR-T$141
- Diamondback Coronary$132
How this compares
$17,823 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $97,378 |
| EntrestoSacubitril/Valsartan | 103 | $85,787 |
| Repatha SureclickEvolocumab | 66 | $69,393 |
| XareltoRivaroxaban | 80 | $53,885 |
| BrilintaTicagrelor | 60 | $27,731 |
| VascepaIcosapent Ethyl | 46 | $19,687 |
| FarxigaDapagliflozin Propanediol | 30 | $18,454 |
| JardianceEmpagliflozin | 13 | $9,769 |
| Praluent PenAlirocumab | 15 | $6,982 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $3,697 |
| ClopidogrelClopidogrel Bisulfate | 287 | $2,120 |
| Rosuvastatin Calcium | 99 | $1,664 |
| Ezetimibe | 87 | $1,600 |
| Metoprolol Succinate | 195 | $1,471 |
| Cilostazol | 90 | $1,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $146 | $97,378141 claims |
| NovartisEntresto | $464 | $85,787103 claims |
| Johnson & JohnsonXarelto | $340 | $53,88580 claims |
| AstraZenecaBrilinta, Farxiga | $64 | $46,18590 claims |
| Boehringer IngelheimJardiance | $81 | $9,76913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Hialeah
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.